The Exchange has sought clarification from Valiant Laboratories Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE has asked Valiant Laboratories to clarify why its financial results for the quarter ended March 31, 2025 were not submitted in the format prescribed by SEBI under Regulation 33 of the Listing Obligations and Disclosure Requirements Regulations. The company's response to the exchange is currently awaited. This is a procedural compliance matter related to the structure or presentation of the submitted results, not a substantive challenge to the numbers themselves. Until the company responds and the exchange is satisfied, the filing remains flagged for clarification.
This is a minor compliance flag and is unlikely to materially affect the stock price. However, repeated or unresolved clarifications could affect investor confidence and signal weak internal financial reporting controls.